AU2015298356B2 - Immunological reagents binding to pd-1 - Google Patents

Immunological reagents binding to pd-1 Download PDF

Info

Publication number
AU2015298356B2
AU2015298356B2 AU2015298356A AU2015298356A AU2015298356B2 AU 2015298356 B2 AU2015298356 B2 AU 2015298356B2 AU 2015298356 A AU2015298356 A AU 2015298356A AU 2015298356 A AU2015298356 A AU 2015298356A AU 2015298356 B2 AU2015298356 B2 AU 2015298356B2
Authority
AU
Australia
Prior art keywords
seq
antibody
nos
cdrs
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015298356A
Other languages
English (en)
Other versions
AU2015298356A1 (en
Inventor
Craig Fenwick
Giuseppe Pantaleo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mabquest SA
Original Assignee
Mabquest SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabquest SA filed Critical Mabquest SA
Publication of AU2015298356A1 publication Critical patent/AU2015298356A1/en
Application granted granted Critical
Publication of AU2015298356B2 publication Critical patent/AU2015298356B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2015298356A 2014-08-05 2015-08-05 Immunological reagents binding to pd-1 Active AU2015298356B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462033177P 2014-08-05 2014-08-05
US62/033,177 2014-08-05
US201462053366P 2014-09-22 2014-09-22
US62/053,366 2014-09-22
US201462093368P 2014-12-17 2014-12-17
US62/093,368 2014-12-17
PCT/IB2015/055943 WO2016020856A2 (en) 2014-08-05 2015-08-05 Immunological reagents

Publications (2)

Publication Number Publication Date
AU2015298356A1 AU2015298356A1 (en) 2017-02-16
AU2015298356B2 true AU2015298356B2 (en) 2020-11-19

Family

ID=53836144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015298356A Active AU2015298356B2 (en) 2014-08-05 2015-08-05 Immunological reagents binding to pd-1

Country Status (13)

Country Link
US (3) US9982053B2 (cg-RX-API-DMAC7.html)
EP (1) EP3177644B1 (cg-RX-API-DMAC7.html)
JP (1) JP6629321B2 (cg-RX-API-DMAC7.html)
KR (1) KR102357893B1 (cg-RX-API-DMAC7.html)
CN (1) CN107074947B (cg-RX-API-DMAC7.html)
AU (1) AU2015298356B2 (cg-RX-API-DMAC7.html)
CA (1) CA2957258C (cg-RX-API-DMAC7.html)
DK (1) DK3177644T3 (cg-RX-API-DMAC7.html)
ES (1) ES2847311T3 (cg-RX-API-DMAC7.html)
PL (1) PL3177644T3 (cg-RX-API-DMAC7.html)
PT (1) PT3177644T (cg-RX-API-DMAC7.html)
SG (1) SG11201700672YA (cg-RX-API-DMAC7.html)
WO (1) WO2016020856A2 (cg-RX-API-DMAC7.html)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US9982052B2 (en) * 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
PL3177644T3 (pl) * 2014-08-05 2021-06-14 MabQuest SA Immunologiczne reagenty wiążące do PD-1
RS62332B1 (sr) 2014-11-26 2021-10-29 Xencor Inc Heterodimerna antitela koja vezuju cd3 i cd20
HRP20201031T1 (hr) 2015-05-29 2020-10-16 Agenus Inc. Anti-ctla-4 protutijela i postupci njihove upotrebe
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
ES2898958T3 (es) 2015-07-30 2022-03-09 Macrogenics Inc Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas
CN108289953B (zh) 2015-09-29 2022-03-11 细胞基因公司 Pd-1结合蛋白及其使用方法
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
US11214617B2 (en) * 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
EP3405497A2 (en) 2016-01-22 2018-11-28 Mabquest SA Immunological reagents
CN106008714B (zh) * 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
IL263542B2 (en) * 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3534950A4 (en) 2016-11-01 2020-05-06 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
SI3535298T1 (sl) * 2016-11-02 2022-01-31 Jounce Therapeutics, Inc. Protitelesa proti pd-1 in njihove uporabe
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
AU2017373945B2 (en) 2016-12-07 2025-01-23 Agenus Inc. Antibodies and methods of use thereof
US11591398B2 (en) 2017-01-06 2023-02-28 Crescendo Biologics Limited Single domain antibodies to programmed cell death protein 1 (PD-1)
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
KR20190103226A (ko) 2017-01-13 2019-09-04 아게누스 인코포레이티드 Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
CN107474135B (zh) * 2017-02-17 2020-08-18 广西医科大学 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用
CN110637031B (zh) 2017-03-04 2024-04-16 湘潭腾华生物科技有限公司 程序性死亡蛋白1(pd-1)的重组抗体及其用途
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
MX2019014577A (es) 2017-06-05 2020-07-29 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y metodos de uso.
MA50084A (fr) 2017-09-04 2020-07-15 Agenus Inc Récepteurs de lymphocytes t qui se lient à des phosphopeptides spécifiques de la leucémie de lignée mixte (mll) et méthodes d'utilisation de ces derniers
US11021540B2 (en) * 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
KR20200083574A (ko) 2017-11-13 2020-07-08 크레센도 바이오로직스 리미티드 Cd137 및 psma에 결합하는 분자
CN108218988B (zh) * 2017-11-29 2019-10-11 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
JP7430924B2 (ja) * 2018-03-22 2024-02-14 ケイレス アーゲー 拮抗的抗原結合タンパク質
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
IL279455B1 (en) 2018-06-20 2025-09-01 Incyte Corp ANTI-PD-1 ANTIBODIES AND THEIR USES
BR112021013157A8 (pt) 2019-01-03 2022-12-06 Inst Nat Sante Rech Med Usos de um inibidor de nrp-1, uso de uma combinação, uso de um anticorpo multiespecífico, método ex vivo para predizer, uso de um inibidor, anticorpo multiespecífico, população de células modificadas, método ex vivo de produção e uso de uma população de células t
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
AU2020322021A1 (en) 2019-07-30 2022-02-10 Pairwise Plants Services, Inc. Morphogenic regulators and methods of using the same
US11629190B2 (en) 2019-08-15 2023-04-18 Oregon State University Canine antibody therapeutic for treating cancer
KR102231974B1 (ko) * 2019-08-23 2021-03-25 한국과학기술원 사람의 프로그램된 세포사멸 단백질(pd-1)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
EP4048063A4 (en) 2019-10-23 2023-12-06 Pairwise Plants Services, Inc. Compositions and methods for rna-templated editing in plants
AU2020372931A1 (en) 2019-10-30 2022-05-12 Pairwise Plants Services, Inc. Type V CRISPR-Cas base editors and methods of use thereof
JP7785002B2 (ja) 2019-11-05 2025-12-12 ペアーワイズ プランツ サービシズ， インコーポレイテッド 対立遺伝子のｒｎａにコードされたｄｎａの置換のための組成物および方法
US20230034677A1 (en) 2019-11-21 2023-02-02 INSERM (Institut National de la Santé et la Recherche (Médicale) Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
WO2021113788A1 (en) 2019-12-06 2021-06-10 Pairwise Plants Services, Inc. Recruitment methods and compounds, compositions and systems for recruitment
CA3169462A1 (en) 2020-01-30 2021-08-05 Pairwise Plants Services, Inc. Compositions, systems, and methods for base diversification
WO2021155084A1 (en) 2020-01-31 2021-08-05 Pairwise Plants Services, Inc. Suppression of shade avoidance response in plants
US20230063560A1 (en) 2020-02-04 2023-03-02 Pairwise Plans Services, Inc. Thornless and/or prickleless rubus plants
CA3172333A1 (en) 2020-02-21 2021-08-26 Pairwise Plants Services, Inc. Improved resistance to soybean cyst nematode through gene editing
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11999946B2 (en) 2020-03-26 2024-06-04 Pairwise Plants Services, Inc. Methods for controlling meristem size for crop improvement
US11882808B2 (en) 2020-03-27 2024-01-30 Pairwise Plants Services, Inc. Methods for improving resistance to soybean rust
US20230175006A1 (en) 2020-04-06 2023-06-08 Pairwise Plants Services, Inc. Methods and compositions for increasing resistance to ear rot and stem rot disease in maize
CN119431532A (zh) 2020-04-16 2025-02-14 成对植物服务股份有限公司 控制分生组织大小以改良作物的方法
BR112022022352A2 (pt) * 2020-05-04 2023-01-10 Inhibrx Inc Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
MX2022014974A (es) 2020-05-26 2023-01-11 Boehringer Ingelheim Int Anticuerpos anti-pd-1.
MX2022015107A (es) 2020-06-02 2023-03-01 Pairwise Plants Services Inc Metodos para controlar el tama?o del meristema para mejorar los cultivos.
AR122661A1 (es) 2020-06-17 2022-09-28 Pairwise Plants Services Inc Métodos para el control del tamaño del meristemo para la mejora de cultivos
CA3187135A1 (en) 2020-06-30 2022-01-06 Pairwise Plants Services, Inc. Compositions, systems, and methods for base diversification
EP4204436A1 (en) 2020-08-28 2023-07-05 Pairwise Plants Services, Inc. Engineered crispr-cas proteins and methods of use thereof
MX2023005150A (es) 2020-11-06 2023-05-26 Pairwise Plants Services Inc Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
BR112023015909A2 (pt) 2021-02-11 2023-11-21 Monsanto Technology Llc Métodos e composições para modificar níveis de citocinina oxidase em plantas
CN117203227A (zh) 2021-02-25 2023-12-08 成对植物服务股份有限公司 用于修饰植物中根结构的方法和组合物
CN113189078B (zh) * 2021-03-04 2024-04-16 吉林大学 一种靶向药物的高通量筛选方法
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
WO2022265905A2 (en) 2021-06-14 2022-12-22 Pairwise Plants Services, Inc. Reporter constructs, compositions comprising the same, and methods of use thereof
EP4355083A1 (en) 2021-06-17 2024-04-24 Pairwise Plants Services, Inc. Modification of growth regulating factor family transcription factors in soybean
UY39827A (es) 2021-06-24 2023-01-31 Pairwise Plants Services Inc Modificación de genes de ubiquitina ligasa e3 hect para mejorar los rasgos de rendimiento
CA3224982A1 (en) 2021-07-01 2023-01-05 Pairwise Plants Services, Inc. Methods and compositions for enhancing root system development
CN113702351B (zh) * 2021-07-14 2024-08-20 吉林大学 一种对天然药物产物进行筛选和垂钓的方法
WO2023019188A1 (en) 2021-08-12 2023-02-16 Pairwise Plants Services, Inc. Modification of brassinosteroid receptor genes to improve yield traits
UY39902A (es) 2021-08-17 2023-03-31 Pairwise Plants Services Inc Métodos y composiciones para modificar genes de histidina quinasa receptores de citoquinina en plant
MX2024002276A (es) 2021-08-30 2024-03-07 Pairwise Plants Services Inc Modificacion de genes de peptidasa de union a ubiquitinaen plantas para mejorar rasgos de rendimiento.
AR126938A1 (es) 2021-09-02 2023-11-29 Pairwise Plants Services Inc Métodos y composiciones para mejorar la arquitectura de las plantas y los rasgos de rendimiento
US20230266293A1 (en) 2021-09-21 2023-08-24 Pairwise Plants Services, Inc. Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same
CN118382634A (zh) 2021-09-21 2024-07-23 成对植物服务股份有限公司 用于减少油菜荚果开裂的方法和组合物
AR127236A1 (es) 2021-10-04 2024-01-03 Pairwise Plants Services Inc Métodos para mejorar la fertilidad de la flor y el rendimiento de semillas
US20230116819A1 (en) 2021-10-07 2023-04-13 Pairwise Plants Services, Inc. Methods for improving floret fertility and seed yield
AR127904A1 (es) 2021-12-09 2024-03-06 Pairwise Plants Services Inc Métodos para mejorar la fertilidad de floretes y el rendimiento de semillas
US20230295646A1 (en) 2021-12-13 2023-09-21 Pairwise Plants Services, Inc. Model editing systems and methods relating to the same
US20250146008A1 (en) 2022-01-06 2025-05-08 Pairwise Plants Services, Inc. Methods and compositions for trichome removal
IL314524A (en) 2022-01-28 2024-09-01 Georgiamune Inc Antibodies to programmed cell death protein 1 that are agonists for PD-1
AR128372A1 (es) 2022-01-31 2024-04-24 Pairwise Plants Services Inc Supresión de la respuesta de evitación de la sombra en las plantas
US20230383271A1 (en) 2022-02-28 2023-11-30 Pairwise Plants Services, Inc. Engineered proteins and methods of use thereof
CN119072487A (zh) 2022-03-02 2024-12-03 成对植物服务股份有限公司 用于改善产量性状的油菜素类固醇受体基因的修饰
CN115015536A (zh) * 2022-03-30 2022-09-06 邹灵龙 一种即时检测pd-1抗体药浓度的试纸条和试剂盒
EP4499842A1 (en) 2022-03-31 2025-02-05 Pairwise Plants Services, Inc. Early flowering rosaceae plants with improved characteristics
CA3247405A1 (en) 2022-04-07 2023-10-12 Pairwise Plants Services, Inc. METHODS AND COMPOSITIONS FOR IMPROVING RESISTANCE TO FUSARIA BROAD OF THE SPINE
EP4511387A1 (en) 2022-04-21 2025-02-26 Pairwise Plants Services, Inc. Methods and compositions for improving yield traits
EP4519428A1 (en) 2022-05-02 2025-03-12 Pairwise Plants Services, Inc. Methods and compositions for enhancing yield and disease resistance
WO2023215809A1 (en) 2022-05-05 2023-11-09 Pairwise Plants Services, Inc. Methods and compositions for modifying root architecture and/or improving plant yield traits
UY40326A (es) 2022-06-27 2023-12-29 Pairwise Plants Services Inc Métodos y composiciones para modificar el escape a la sombra en plantas
EP4547692A1 (en) 2022-06-29 2025-05-07 Pairwise Plants Services, Inc. Methods and compositions for controlling meristem size for crop improvement
CA3259679A1 (en) 2022-06-29 2024-01-04 Pairwise Plants Services, Inc. METHODS AND COMPOSITIONS FOR REGULATING MERISTEMUM SIZE TO IMPROVE CROP PRODUCTION
US20240043857A1 (en) 2022-08-04 2024-02-08 Pairwise Plants Services, Inc. Methods and compositions for improving yield traits
CA3264244A1 (en) 2022-08-11 2024-02-15 Pairwise Plants Services, Inc. METHODS AND COMPOSITIONS FOR REGULATING MERISTEME SIZE FOR CROP IMPROVEMENT
US20240090466A1 (en) 2022-09-08 2024-03-21 Pairwise Plants Services, Inc. Methods and compositions for improving yield characteristics in plants
WO2024130102A2 (en) 2022-12-16 2024-06-20 Pairwise Plants Services, Inc. Fusion proteins comprising an intein polypeptide and methods of use thereof
CN120359295A (zh) 2022-12-21 2025-07-22 成对植物服务股份有限公司 工程化蛋白质和其使用方法
WO2024173622A1 (en) 2023-02-16 2024-08-22 Pairwise Plants Services, Inc. Methods and compositions for modifying shade avoidance in plants
US20240327811A1 (en) 2023-03-01 2024-10-03 Pairwise Plants Services, Inc. Engineered proteins and methods of use thereof
AR132019A1 (es) 2023-03-02 2025-05-21 Pairwise Plants Services Inc Métodos y composiciones para modificar la evitación de la sombra en plantas
AR132071A1 (es) 2023-03-09 2025-05-21 Pairwise Plants Services Inc Modificación de genes de la vía de señalización de brasinoesteroide para mejorar rasgos de rendimiento en plantas
AU2024248777A1 (en) 2023-03-30 2025-10-02 Pairwise Plants Services, Inc. Methods and compositions for reducing thorns or prickles in plants
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
UY40746A (es) 2023-05-18 2024-12-13 Pairwise Plants Services Inc Métodos y composiciones para mejorar las características de rendimiento de las plantas
AR133164A1 (es) 2023-07-18 2025-09-03 Pairwise Plants Services Inc Métodos y composiciones para modificar la arquitectura radicular en plantas
AR133310A1 (es) 2023-07-27 2025-09-17 Pairwise Plants Services Inc Métodos y composiciones para modificar rasgos de rendimiento de las plantas
AR133901A1 (es) 2023-09-21 2025-11-12 Pairwise Plants Services Inc Plantas de frambuesa negra de floración temprana con características mejoradas
WO2025072430A1 (en) 2023-09-26 2025-04-03 Pairwise Plants Services, Inc. Crispr-cas fusion proteins with adenine base editor functionality, compositions comprising the same, and methods of use thereof
US20250129348A1 (en) 2023-10-09 2025-04-24 Pairwise Plants Services, Inc. Circular permutants, compositions comprising the same, and methods of use thereof
WO2025080600A1 (en) 2023-10-11 2025-04-17 Pairwise Plants Services, Inc. Methods and compositions for improving crop yield traits
US20250207154A1 (en) 2023-12-21 2025-06-26 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
WO2025178902A1 (en) 2024-02-22 2025-08-28 Pairwise Plants Services, Inc. Methods and compositions for improving yield characteristics in plants
WO2025252857A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale Il-15 muteins with ph-dependent binding for il-15ralpha
WO2025252855A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
US12428636B1 (en) 2024-07-08 2025-09-30 Pairwise Plants Services, Inc. Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988006626A1 (en) 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
WO1991013157A1 (en) 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2110682A1 (en) 1991-06-06 1992-12-10 Charles K. Stover Induction of ctl responses to foreign antigens expressed in mycobacteria
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
JP3454275B2 (ja) 1992-06-05 2003-10-06 佑 本庶 プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ
AU7203194A (en) 1993-06-04 1995-01-03 New York University Bispecific human monoclonal antibodies specific for human immunodeficiency virus
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP1445264B1 (en) 2001-07-31 2011-09-14 Ono Pharmaceutical Co., Ltd. Substance specific to pd-1
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
EP1896582A4 (en) * 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
MX349137B (es) 2005-06-08 2017-07-13 Dana-Farber Cancer Inst Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009114335A2 (en) * 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
TW201007669A (en) 2008-08-01 2010-02-16 Integrated Solutions Technology Inc A display driving device and the driving method thereof
EP2342228B1 (en) * 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029435A1 (en) * 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011100841A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
WO2011110604A1 (en) * 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012062218A1 (en) 2010-11-11 2012-05-18 The University Of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
US9090994B2 (en) 2011-06-08 2015-07-28 Nanjingjinsirui Science & Technology Biology Corp. Antibody humanization by framework assembly
TWI835048B (zh) * 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
EP2817619B1 (en) * 2012-02-23 2018-07-25 Sloan Kettering Institute For Cancer Research Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
EP2904011B1 (en) * 2012-10-02 2017-08-23 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
EA034666B1 (ru) * 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PL3177644T3 (pl) * 2014-08-05 2021-06-14 MabQuest SA Immunologiczne reagenty wiążące do PD-1
US9982052B2 (en) * 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
US11214617B2 (en) * 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
EP3405497A2 (en) * 2016-01-22 2018-11-28 Mabquest SA Immunological reagents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056875A1 (en) * 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor

Also Published As

Publication number Publication date
WO2016020856A2 (en) 2016-02-11
US20220169733A1 (en) 2022-06-02
JP6629321B2 (ja) 2020-01-15
US20190106493A1 (en) 2019-04-11
DK3177644T3 (da) 2021-01-11
WO2016020856A3 (en) 2016-03-31
US20170226210A1 (en) 2017-08-10
CN107074947A (zh) 2017-08-18
EP3177644B1 (en) 2020-10-07
US11130807B2 (en) 2021-09-28
CA2957258A1 (en) 2016-02-11
PL3177644T3 (pl) 2021-06-14
EP3177644A2 (en) 2017-06-14
CA2957258C (en) 2023-11-07
JP2017531028A (ja) 2017-10-19
AU2015298356A1 (en) 2017-02-16
CN107074947B (zh) 2021-04-09
US9982053B2 (en) 2018-05-29
PT3177644T (pt) 2021-01-13
KR102357893B1 (ko) 2022-02-04
ES2847311T3 (es) 2021-08-02
KR20170069996A (ko) 2017-06-21
SG11201700672YA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
US11130807B2 (en) Immunological reagents
US10294299B2 (en) Immunological reagents
US9982052B2 (en) Immunological reagents
US20210009661A1 (en) HIV Binding Agents
US20220259315A1 (en) Immunological Reagents
WO2016077720A1 (en) Binding agents and uses thereof
WO2020012435A1 (en) Hiv binding agents
JP7678790B2 (ja) Ｈｉｖ結合剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)